Address
OrbiMed Advisors LLC
767 Third Avenue
30th Floor
New York, NY 10017
United States
Phone
Website
Industry
Recent investment activity
KANDO id: 29979
Corporate information
Official name
OrbiMed Advisors Limited Liability Company
Registration country
Funds managed
| Fund | Type | Vintage | Currency | Committed capital | IRR | x |
|---|---|---|---|---|---|---|
| OrbiMed Private Investments VII | 2017 | |||||
| OrbiMed Private Investments VI LP | 2015 | |||||
| Orbimed Global Healthcare Associates Fund LP | Hedge fund | 2014 | ||||
| OrbiMed Global Healthcare Fund LP | Hedge fund | 2014 | ||||
| OrbiMed Global Healthcare Fund Ltd | Hedge fund | 2013 | ||||
| OrbiMed Healthcare Investments Fund (Offshore) LP | 2013 | USD | 29,575,000 | |||
| OrbiMed Private Investments V LP | 2013 | |||||
| OrbiMed Private Investments IV LP | Venture | 2009 | 45.20 % | 2.78 x | ||
| OrbiMed Private Investments III LP | Venture | 2006 | 21.30 % | 2.54 x | ||
| OrbiMed Partners II LP | Hedge fund | 1998 | ||||
| OrbiMed Partners LP | Hedge fund | 1993 | ||||
| OrbiMed Healthcare Investments Trust | ||||||
| OrbiMed Royalty Opportunities II LP |
Funding rounds
Investment preferences
Investment activity status
Active investor
Selected investments
Displaying 1 - 25 of 114| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
|
Blossomhill Therapeutics Inc | Biotechnology company focused on oncology and autoimmune disorders. | Series A Initial investment | |||
|
Armo BioSciences Inc | Late-stage immuno-oncology company. | Series C-1 Follow-on investment | |||
|
Nutrinia Ltd | Developer of an oral formulation of insulin for intestinal malabsorption in preterm newborns and SBS in infants. | Series D Follow-on investment | |||
|
Tricida Inc | Series C Follow-on investment | ||||
|
|
Tricida Inc | Series B Follow-on investment led the round | ||||
|
|
Tricida Inc | Series A led the round | ||||
|
Natera Inc | Biotechnology company providing preconception and prenatal genetic testing services. | Venture Initial investment led the round | |||
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series F | |||
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_company.png?itok=-3VkoHwg){kind=icon}
|
Cleave Biosciences Inc | Drug development company focused on novel targets in cellular protein homeostasis pathways | Series A | |||
|
|
Ambit Biosciences Inc | A biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer. | Series D | |||
|
Complete Genomics Inc | Series E | ||||
|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series E Follow-on investment | |||
|
|
Selecta Biosciences Inc | A biotechnology company developing a new class of synthetic nanoparticle vaccines. | Series C | |||
|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series D Follow-on investment | |||
|
Adimab LLC | Developer of a human antibody discovery platform in yeast. | Series D | |||
|
|
Complete Genomics Inc | Series D | ||||
|
|
Amnis Corp | A biotechnology company developing high throughput laboratory automation tools that use a novel molecule detection technology. | Series D | |||
|
|
ARYx Therapeutics Inc | N/A Initial investment | ||||
|
|
Biolex Therapeutics Inc | Series D | ||||
|
|
Innovative Spinal Technologies Inc | Spine technology company. | Series C | |||
|
|
Glaukos Corp | Series D | ||||
|
|
InteKrin Therapeutics Inc | Biopharmaceutical company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders.. | Series C | |||
|
|
Avanir Pharmaceuticals Inc | A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. | N/A | |||
|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series C Initial investment | |||
|
|
Enobia Pharma Corp | Series B |
![[node:title] photo](/sites/default/files/styles/icon/public/default_images/_person_0.png?itok=nkWWtsDD){kind=icon}